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Abstract It is well known that signiﬁcant metabolic
change take place as cells are transformed from normal to
malignant. This review focuses on the use of different
bioinformatics tools in cancer metabolomics studies. The
article begins by describing different metabolomics tech-
nologies and data generation techniques. Overview of the
data pre-processing techniques is provided and multivariate
data analysis techniques are discussed and illustrated with
case studies, including principal component analysis,
clustering techniques, self-organizing maps, partial least
squares, and discriminant function analysis. Also included
is a discussion of available software packages.
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1 Introduction
A signiﬁcant role in cancer initiation and progression is
attributed to changes in RNA and protein expression levels
and regulation (Byrum et al. 2010; Chari et al. 2010; Fink-
Retter et al. 2009; Korkola and Gray 2010; Larkin et al.
2010). However, changes in small molecules also provide
important mechanistic insights into cancer development.
There is a strong body of evidence supporting the impor-
tant role of metabolic regulation in cancer. Malignant cells
undergo signiﬁcant changes in metabolism including a re-
distribution of metabolic networks (Boros et al. 2003).
These metabolic changes result in different metabolic
landscapes in cancer cells versus normal cells. Metabolo-
mics, as a global approach, is especially useful in identi-
fying overall metabolic changes associated with a
particular biological process and ﬁnding the most affected
metabolic networks. Moreover, metabolomics provides an
additional layer of information that can be linked with
transcriptomics and proteomics data to obtain a compre-
hensive view of a biological system.
Metabolomics is a relatively new ﬁeld in genomics
research but it is gaining broader recognition in the cancer
community. Most cancer metabolomics studies to date
have been done using metabolic ﬁngerprinting or proﬁling
with NMR spectroscopy of tissue extracts or in vivo
magnetic resonance spectroscopy. Using NMR spectros-
copy techniques it is possible to differentiate several tumor
G. Blekherman  R. Laubenbacher  D. F. Cortes  P. Mendes 
V. Shulaev
Virginia Bioinformatics Institute, Washington St. 0477,
Blacksburg, VA 24061, USA
R. Laubenbacher  P. Mendes  F. M. Torti  S. Akman 
S. V. Torti  V. Shulaev
Comprehensive Cancer Center, Wake Forest University School
of Medicine, Winston-Salem, NC 27157, USA
P. Mendes
School of Computer Science and Manchester Centre
for Integrative Systems Biology, The University of Manchester,
131 Princess St, Manchester, M1 7DN, UK
F. M. Torti  S. Akman
Department of Cancer Biology, Wake Forest University School
of Medicine, Winston-Salem, NC 27157, USA
S. V. Torti
Department of Biochemistry, Wake Forest University School
of Medicine, Winston-Salem, NC 27157, USA
V. Shulaev (&)
Department of Biological Sciences, College of Arts
and Sciences, University of North Texas, 1155 Union Circle
#305220, Denton, TX 76203, USA
e-mail: shulaev@unt.edu
123
Metabolomics (2011) 7:329–343
DOI 10.1007/s11306-010-0270-3types in humans and in animal models (Beckonert et al.
2010; Cheng et al. 1996; Devos et al. 2004; Lukas et al.
2004; Merz and Serkova 2009; Tate et al. 1998, 2000). But
while techniques based on magnetic resonance have the
advantage of being non-invasive, they have low sensitivity
and cannot detect molecules at low concentrations. Mass
spectrometry methods provide advantage of higher sensi-
tivity and are more appropriate for in vitro studies
(Patterson et al. 2010; Qiu et al. 2010; Sugimoto et al.
2010; Urayama et al. 2010; Want et al. 2010).
Similar to transcriptomics and proteomics, metabolo-
mics generates large amounts of data. Storing, pre-pro-
cessing and multivariate statistical analysis of these data
provide a signiﬁcant challenge and require specialized
mathematical, statistical and bioinformatics tools
(reviewed in (Katajamaa and Ores ˇic ˇ 2007; Madsen et al.
2010; Shulaev 2006)). Metabolomics experiments generate
a large volume of specialized data that are complex and
multi-dimensional. Storing, organizing and retrieving the
data and associated metadata requires properly designed
databases. The analysis of these data sets is equally chal-
lenging and new analysis algorithms are still being devel-
oped. Multivariate statistical analysis of the metabolomics
data in many cases utilizes the same approaches as the
analysis of other genomic data. However, metabolomics
has unique bioinformatics needs in addition to others
common in microarray or proteomics data due to the fact
that it is generated by multiple analytical platforms and
requires extensive data pre-processing. Major areas where
developments in data analysis techniques are crucial for
further progress of metabolomics include: data and infor-
mation management, raw analytical data processing, met-
abolomics standards and ontology, statistical analysis and
data mining, data integration, and mathematical modeling
of metabolic networks within the framework of systems
biology.
This article aims at providing a basic overview of
metabolomics data analysis, including practical applica-
tions and metabolomics software, as it is being used for
cancer research. We discuss major multivariate data anal-
ysis techniques, including principal component analysis,
clustering techniques, self-organizing maps, partial least
squares, and discriminant function analysis., and illustrate
them with case studies.
2 Metabolomics technology and data generation
There are three major approaches used in metabolomics
studies: targeted analysis, metabolite proﬁling and meta-
bolic ﬁngerprinting (Fiehn 2002; Shulaev 2006). Targeted
analysis is used to measure the concentration of limited
numbers of known metabolites precisely. It is a truly
quantitative approach and provides low limits of detection
for known metabolites. Metabolite proﬁling usually is an
untargeted high throughput measurement of the levels of a
large number of metabolites. The advantage of metabolite
proﬁling is that, unlike targeted analysis, it does not require
the compounds of interest to be known a priori and
therefore it can be used to identify novel metabolic bio-
markers or survey the global metabolic changes in the
system. Metabolic ﬁngerprinting considers the total
metabolite proﬁle, or ﬁngerprint, as a unique pattern
characterizing a snapshot of the metabolism in a particular
cell line or tissue.
Analytical techniques used for metabolite proﬁling
include nuclear magnetic resonance (NMR) (Jordan and
Cheng 2007; Serkova and Glunde 2009), Gas Chroma-
tography–Mass Spectrometry (GC–MS) (Asiago et al.
2010; Qiu et al. 2010; Yang et al. 2007), Liquid Chroma-
tography–Mass Spectrometry (LC–MS) (Chen et al. 2009;
Kind et al. 2007; Yang et al. 2010), Capillary Electro-
phoresis–Mass Spectrometry (CE–MS) (Soga 2007), and
Fourier transform infrared spectroscopy (FT-IR) (Johnson
et al. 2003; Kim et al. 2010). Advantages and downside of
each techniques for metabolomics were reviewed else-
where (Fiehn 2002; Shulaev 2006; Sumner et al. 2003).
Due to diversity in cellular metabolites’ chemical and
physical properties there is no single analytical technique
that can analyze all metabolites simultaneously. Usually a
combination of analytical techniques is used to cover as
broad a range of metabolites as possible. This presents a
unique challenge for data analysis since each analytical
technique generates a speciﬁc data structure and has to be
processed with a specialized informatics tool.
3 Metabolomics standards and metadata
Metabolomics, like other genomics research areas, requires
standards of data management, analysis and reporting to be
adopted by community (Bino et al. 2004; Castle et al. 2006;
Grifﬁn and Steinbeck 2010; Jenkins et al. 2004; Lindon
et al. 2005; Sansone et al. 2007). This is critical consid-
ering the growing number of metabolomics studies, the
urgent need to store metabolomics data in genomics dat-
abases, and the ability to compare data generated in dif-
ferent labs (Castle et al. 2006). Metabolomics Society
(http://www.metabolomicssociety.org/) working group is
currently working on the development of metabolomics
standards to be adopted by the community (http://
www.metabolomicssociety.org/mstandards.html). The ﬁrst
step in devising standards for metabolomics experiments
was the development of the Minimum Information about a
Metabolomics Experiment (MIAMET) (Bino et al. 2004).
MIAMET deﬁnes the minimum information required to
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mental data and metadata (data about the experiment).
4 Metabolomics data analysis
Major steps in metabolomics data analysis include raw data
pre-processing, spectral deconvolution and component
detection, data normalization and multivariate statistical
analysis.
4.1 Raw data pre-processing
The ﬁrst step in metabolomics data analysis is the pro-
cessing of the raw data and it involves several steps
depending on the methodology used (Hansen 2007). Due to
the complex nature of metabolomics data, when the
objective is to identify and measure as many different
metabolites as possible, raw data processing is a very
important step in data analysis. Raw data processing for
different techniques used in metabolomics have been
extensively reviewed (Hansen 2007; Katajamaa and Ores ˇic ˇ
2007; Scalbert et al. 2009; Schripsema 2010; Spraul et al.
1994). Therefore, here we will just introduce the major
concepts on how the raw data can be processed and
transformed into the format suitable for multivariate sta-
tistical analysis or machine learning techniques. More
detail on the individual raw data processing techniques the
reader can ﬁnd in the referenced manuscripts.
Typically NMR data show variation in peak width,
shape and position due to differences in sample matrix (i.e.,
pH or ionic strength) or variations in instrument perfor-
mance. Therefore, raw data should be pre-processed to
correct these variations. NMR data pre-processing usually
include correction of line width using line broadening
parameter (i.e., using tuned exponential multiplication),
Fourier transformation, phase correction with user prede-
ﬁned phase constants, and positioning and scaling
(Lommen et al. 1998). NMR data processing techniques
include binning, peak picking, and spectrum deconvolution
(Schripsema 2010). Binning or bucketing is the most
common routine for NMR data processing prior to multi-
variate statistical analysis or ﬁngerprinting (Beckwith-Hall
et al. 1998; Spraul et al. 1994). Binning is achieved by
separating the spectra into multiple discrete regions (hixels
or buckets) which are than averaged and integrated. This
leads to substantial information loss but corrects the data
for peak shifts due to pH or ionic strength variation among
samples. The other advantage of binning is signiﬁcant data
reduction which simpliﬁes subsequent data analysis. Usu-
ally the bucket width is ﬁxed to 0.04 ppm resulting in the
reduction of the high resolution NMR spectrum from of 16
to 64 K data points to on average of 250 data points.
Binned data can be directly imported into numerous sta-
tistical packages for multivariate analysis. The other
approach to NMR data pre-processing is spectra alignment
and peak picking. Several NMR spectral alignment algo-
rithms can be found in the literature, including linear ﬁt
method, described by Vogels et al. (1996), or automatic
removal of frequency shifts in spectra by PCA, described
by Brown and Stoyanova (1996).
The other approach to NMR data processing is to de-
convolute the spectra into individual components (see
review by Schripsema (2010)). This approach has an
advantage over other pre-processing approaches as it
allows the identiﬁcation and quantitation of individual
components in the mixture from the complex NMR spec-
trum. Weljie et al. (2006) described a novel technique of
deconvoluting complex spectra based on mathematical
modeling of individual NMR resonances from pure com-
pound spectra to create a component database followed by
database search to identify and quantify metabolites in
complex spectra of biological matrices. Authors deﬁned
this approach as ‘‘targeted proﬁling’’ and validated it
against a ‘‘spectral binning’’ analysis. The technique
proved to be very stable in PCA-based pattern recognition
analysis, insensitive to water suppression effects, relaxation
times, and scaling factors. As unambiguous compound
identiﬁcation from the complex one-dimensional
1H-NMR
spectrum can be complicated; several two-dimensional
NMR techniques, including 2D-COSY (Correlation Spec-
troscopy), 2D-HMBC (Heteronuclear Multiple Bond
Coherence), 2D-HSQC (Heteronuclear Single Quantum
Coherence), 2D-TOCSY (Total Correlation Spectroscopy)
(Ludwig et al. 2009), 2D-HRMAS (High Resolution Magic
Angle Spinning)(Bayet-Robert et al. 2010) and 2D-JRES
(J-resolved spectroscopy) (Fonville et al. 2010), were used
in metabolomics studies to increase metabolite speciﬁcity
and improve quantitation (Ludwig and Viant 2010;
Schripsema 2010). Application of two-dimensional tech-
niques in metabolomics studies is rather limited due to a
long time required to acquire 2D spectrum (i.e., it requires
close to 20 h to acquire typical 2D TOCSY spectrum to
achieve the same sensitivity as 1D spectrum acquired in
few minutes (Tang et al. 2004). 2D-JRES NMR spectros-
copy provides analysis speed advantage over other two-
dimensional techniques. It takes about 20 min to acquire a
2D spectrum of a metabolite mixture with relatively little
convolution of signals at the same time signiﬁcantly
improving spectral assignment and accurate quantitation
(Ludwig and Viant 2010).
Mass spectrometry data processing involves noise
reduction, spectrum deconvolution, peak detection and
integration, chromatogram alignment, component detec-
tion, identiﬁcation and quantitation (Katajamaa and Ores ˇic ˇ
2007). Raw mass spectrometry data, in addition to real
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is a slowly varying part of the spectral signal, while noise
includes rapid spikes in the intensity of the signal. To
remove noise from data several algorithms have been
developed and are currently implemented in both com-
mercial and publicly available software. Typically, moving
window ﬁlters are most often used to remove the noise
from the data (Hansen 2007). Other noise ﬁltering algo-
rithms include median ﬁltering (Hastings et al. 2002),
Savitsky-Golay ﬁlter based on polynomial regression
(Savitzky and Golay 1964), and wavelet transform (Chen
et al. 2010; Coombes et al. 2005). Next step in raw data
processing is spectral deconvolution. Deconvolution or
component detection is used to separate two or more co-
eluting (or overlapping) components in the mass spectral
data. Several deconvolution algorithms are implemented in
both commercial and public software. GC–MS data are
often processed using AMDIS (Automated Mass Spectral
Deconvolution and Identiﬁcation System, http://chemdata.
nist.gov/mass-spc/amdis/) software that utilizes well des-
cribed algorithms, has proven to be extremely useful in
processing of the GC–MS data (Halket et al. 1999). ESI-
LC–MS data can be processed using variety of algorithms,
including component detection algorithm (CODA) (Windig
et al. 1996), ‘‘windowed mass selection method’’ (WMSM)
(Fleming et al. 1999), singular value decomposition
(SVD), sequential paired covariance (SPC) (Muddiman
et al. 1995), or higher order sequential paired covariance
(HO-SPC) (Muddiman et al. 1997).
Following the deconvolution process it is necessary to
deﬁne, integrate and quantitate the peaks corresponding to
individual components. Peak detection approaches in mass
spectrometry data were recently reviewed by Katajamaa
and Ores ˇic ˇ (2007) who reviewed three major strategies to
feature detection: (1) peak detection performed separately
in two dimensions (retention time and m/z), (2) by
extracting each individual ion chromatogram and process-
ing them independently, and (3) ﬁtting a model to the data.
The ﬁrst method identiﬁes the features with the intensities
above the deﬁned threshold independently in the retention
time and m/z directions and the ones that meat both
threshold criteria are deﬁned as peaks. Second method
relies on identifying peaks in a discrete set of extracted ion
chromatograms, each representing a small range of m/z
values. The third strategy is based on ﬁtting two- or three-
dimensional model of isotope pattern to raw signal. All
these approaches allow generating peak lists with quanti-
tative information on individual metabolites/components
for subsequent multivariate analysis of datasets.
A typical metabolomics experiment involves a large
number of samples. Due to many variations, such as
instrument or chromatographic column performance, buf-
fer composition, matrix complexity, or environmental
conditions, retention time ﬂuctuates over a set of chro-
matograms. To correct for this retention time ﬂuctuations,
chromatogram should be aligned to compare same features
in a dataset. Detailed review of the different alignment
strategies and algorithm can be found in recent review of
mass-spectrometry data processing in metabolomics by
Katajamaa and Ores ˇic ˇ (2007). Alignment allows compar-
ing large datasets where samples were analyzed over per-
iod of time and sometime on different instruments.
4.2 Multivariate analysis
Metabolomics data can be analyzed with a wide range of
statistical and machine-learning algorithms. These can be
classiﬁed in two major classes: unsupervised and super-
vised algorithms (Mendes 2002).
Unsupervised methods that have been used in analyzing
metabolomics data are principal component analysis (PCA)
(Odunsi et al. 2005), hierarchical clustering (Eisen et al.
1998), and self-organizing maps (Tamayo et al. 1999).
Supervised methods include ANOVA (Churchill 2004),
partial least squares (PLS) (Musumarra et al. 2003), sup-
port vector machines, k-Nearest neighbors, and discrimi-
nant function analysis (DFA) (Raamsdonk et al. 2001).
Several excellent textbooks (Hastie et al. 2001; Johnson
and Wichern, 2007; Quinn and Keough 2002; Tettamanzi
and Tomassini 2001; Wilcox 2005) provide extensive
discussion on both the mathematical and practical aspects
of the different statistical and machine learning algorithms
for data analysis, mining, inference and prediction; there-
fore, here we will only outline major methods widely used
for metabolomics data analysis and illustrate them with
case studies from cancer research.
4.2.1 Data normalization, scaling and dimensionality
reduction
Before statistical analysis metabolomics data have to be
normalized to account for differences in metabolite
recoveries during the extraction process or systematic
errors due to instrument performance. Normalization can
be achieved by either using single or multiple internal
standards spiked into the sample prior to or during the
extraction or by using various normalization factors (Sysi-
Aho et al. 2007).
Metabolomics data, like other ‘‘omic’’ data, are under-
determined, meaning that they contain many more vari-
ables than samples (Kohane et al. 2003). In a typical
‘‘omic’’ experiment an average of several hundreds to tens
of thousands of variables are measured (i.e., all the genes in
a microarray experiment, or hundreds of metabolites in a
metabolomics study), but only a relatively small number of
samples are collected to examine this high-dimensional
332 G. Blekherman et al.
123space. For proper statistical analysis of these data it is
necessary to reduce the number of variables in order to
obtain uncorrelated features in the data. This can be best
achieved either through signiﬁcance methods in ANOVA
and t-tests, through linear combinations of variables in
PCA, or by using evolutionary algorithms such as genetic
algorithms or genetic programming. Evolutionary algo-
rithms are usually carried out in combination with a second
analysis algorithm (e.g., PLS or DFA) that search for
combinations of variables most effective in the secondary
algorithm, and are guided by principles of evolution and
selection of species (reviewed by Pena-Reyes and Sipper
2000). Evolutionary algorithms have been successfully
applied to metabolomics data (Kell 2002).
4.2.2 Principal component analysis (PCA)
PCA is an unsupervised statistical data analysis method
that is used for dimension reduction and visualization of
the data. The goal is to ﬁnd a way to represent high
dimensional data by a projection into a small dimensional
subspace, without losing the important features of the data.
PCA ﬁnds a small dimensional subspace such that the
orthogonal projection of the data into this subspace moves
the data points as little as possible. This produces a small
dimensional representation of the original data that can be
used for visualization or more sophisticated methods of
data analysis. Since we are minimizing the displacement of
the points, we can hope that the small dimensional repre-
sentation captures some important features of the data.
An equivalent way of looking at PCA is that it ﬁnds a
small dimensional subspace such that the orthogonal pro-
jection of the data into this subspace captures as much
variance of the original data as possible.
More precisely, PCA starts by ﬁnding the one dimen-
sional subspace that captures the most variance. This
subspace is called the ﬁrst Principal Component (PC). We
think of the variance in the data that is not captured by the
ﬁrst PC as left-over variance. Next PCA ﬁnds the one
dimensional subspace that captures as much left-over var-
iance as possible. This subspace is called the second
Principal Component. The process can be repeated to
generate as many PCs as desired. It is also possible to have
PCA generate as many principal components as necessary
to capture a certain percentage of the variance in the data,
as opposed to generating a ﬁxed number of PCs.
Each Principal Component is orthogonal (perpendicular)
to all other PCs. The best two dimensional subspace for
capturing variance is the span of the ﬁrst two PCs. The best
three dimensional subspace is the span of the ﬁrst three PCs
and so on. Equivalently, these are the best subspaces for
minimizing the displacement that orthogonal projection
onto this subspace causes.
Advantages of using PCA: PCA has been extensively
used in metabolomics data analysis and it is a well estab-
lished method and can be performed with a variety of
statistical analysis packages. PCA has a very natural geo-
metrical interpretation in terms of minimizing the dis-
placement caused by projection of the data onto a small
dimensional subspace. It provides a good visualization tool
for the data, by looking at the projection into the best two
(or three) dimensional subspace. Since the Primary Com-
ponents are orthogonal to each other, this is often referred
to as plotting PCs against each other.
Downside of using PCA: The principal components are
linear combinations of variables that explain the most
variance. As such PCA is inherently biased toward
selecting (assigning large coefﬁcients/weights) the vari-
ables with large variance. The variables that are good
differentiators but have relatively small variance are unli-
kely to be picked up by PCA. Since metabolomics strives
to analyze the whole metabolome, it is actually likely that
there are many variables unrelated to the problem in
question that possess large variance. These variables will
obscure the true differentiating variables when using PCA.
Another important disadvantage is that the Primary
Components are linear combinations of all the variables.
Therefore, PCA is not effective in singling out a small
group of important metabolites. It is possible to use
VARIMAX rotation to ﬁnd new orthogonal axis that have
the same span as PCs, but are combinations of fewer
variables. However, this is not guaranteed to substantially
improve results.
4.2.2.1 Example of using PCA: detecting epithelial ovar-
ian cancer In Odunsi et al. (2005) metabolic proﬁles of
human serum were used in detecting Epithelial Ovarian
Cancer (EOC). Samples were obtained from 53 individuals
with EOC, 12 patients with benign cysts and 38 healthy
women. The samples were analyzed using
1H-NMR spec-
troscopy and each spectrum was reduced to 200–250 inte-
gral segments of equal width. Each variable was Pareto-
scaled to dampen the tendency of PCA to select the
variables with highest variance. In Pareto scaling a variable
is divided by the square root of its variance. This does not
eliminate high variance entirely, which may be undesirable,
but it gives variables with lower variances a better chance to
be detected by PCA.
The data was separated into three different subsets:
premenopausal women and cancer patients, postmeno-
pausal women and cancer patients and one with benign cyst
and cancer patients. PCA was applied to each of the subsets
and two dimensional plots of PC1 versus PC2 were gen-
erated and analyzed.
The plots showed that the projection onto the ﬁrst two
Primary Components was effective in separating cancer
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cases. When all samples were analyzed together the
patients with benign cysts overlapped with healthy patients,
but there was separation between cancer and non-cancer
samples. This suggests that metabolomics may be useful in
early detection of epithelial ovarian cancer. The loadings
(coefﬁcients) used in PCA were studied in search of
markers that distinguish EOC from normal samples. Sev-
eral potential markers with high loadings such as sugar
hydrogens and 3-hydroxybutyrate were identiﬁed, sug-
gesting how the metabolic proﬁle of cancer patients is
altered by the disease.
4.2.3 Partial least squares (PLS)
PLS is a regression based method of data analysis. The
underlying idea of PLS is that although we collect highly
multidimensional data, the phenomenon under investiga-
tion can be explained using a relatively small number of
factors. PLS computes these factors to which linear
regression is then applied.
In data analysis linear regression is used to ﬁnd the best
linear predictor of some variables Y based on the dependent
variables X (sample readings). For example, we can try to
build a regression model to predict the risk of developing
heart disease based on cholesterol readings and weight of
the patient, along with other factors.
When we are concerned with classiﬁcation problems,
such as cancer versus non-cancer or distinguishing differ-
ent types of cancer, we do not have quantitative measure-
ments for the variable that we are trying to predict, only the
division of samples into different classes. In this case we
set the variable Y to have entry 0 for all samples in the ﬁrst
class, entry 1 for all samples in the second class and so on.
In case of PLS, this is called PLS Discriminant Analysis or
PLS-DA. Unlike PCA, this is a supervised method of data
analysis, the separation of samples into different groups is
crucial to building the model.
PLS differs from the usual linear regression in that PLS
does not just predict independent variables Y based on the
dependent variables X. Instead, PLS tries to ﬁnd a small
dimensional subspace, such that the projection into this
subspace does not change the dependent variables X very
much, and at the same time, the coordinates of this new
subspace are good predictors of Y. This corresponds to the
idea that the variables Y can be predicted using a small
number of factors (thus a projection to a small dimensional
subspace).
In this way PLS is related to the Principal Component
Regression, where Principal Components of X from PCA
are used to predict the independent variables Y. This also
allows PLS to handle data sets with highly correlated
variables, which is often the case in metabolomics. Linear
Regression tends to not work well in these instances.
The output of PLS is similar to the output of PCA. PLS
generates a list of orthogonal vectors (components), which
we can think of as PLS version of Principal Components of
PCA. The PLS components are the factors that ‘‘best
explain’’ the behavior of independent variables Y and they
span the subspace onto which the dependent variables X are
projected. We can choose the number of PLS components
to be used.
The projection of the data on the ﬁrst several compo-
nents can be used for visualization or dimension reduction
in the same way as with PCA. The PLS components are
further used to construct a linear regression model for the
independent variables Y. The regression model is used in
predicting the classes of unknown samples.
Advantages of using PLS: PLS is a well established
method in the ﬁeld of chemometrics and it has also been
applied in bioinformatics, social sciences and other ﬁelds.
There are available software packages that perform PLS,
although it is not as ubiquitous as PCA. PLS does not have
the same tendency to gravitate toward high variance vari-
ables that PCA does. However, it does not have the simple
geometrical interpretation of PCA. PLS provides a tool for
visualization and dimension reduction in the same way as
PCA.
Downside of using PLS: PLS shares the other disad-
vantage of PCA in that its components are linear combi-
nations of all the variables. It is often not possible to single
out a small group of variables that are responsible for
classiﬁcation into different groups.
4.2.3.1 Example of using PLS: using
1H-NMR-based
metabolomics for prognosis of high risk leukemia
patients Chronic lymphocytic leukemia (CLL) is a dis-
ease with varying clinical course and survival rates.
Roughly one third of the patients require immediate
treatment while another third do not require treatment and
have long survival rates. The remaining third exhibits a
passive phase followed by disease progression. An early
diagnostic method for predicting disease progression is
therefore of utmost importance.
The mutational status of the immunoglobulin heavy
chain variable region (IGHV) of CLL cells has been shown
to provide useful prognostic information. However, the
cost and difﬁculty of IGHV sequencing led to a search for
alternative prognostic markers.
MacIntyre and co-authors (MacIntyre et al. 2010) used
metabolic proﬁles of serum of leukemia patients to provide
an alternative method of predicting IGHV mutation.
Twenty nine samples were gathered from untreated early
stage leukemia patients along with nine control samples. Of
the 29 leukemia samples 19 came from patients with
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mutated IGHV region.
The samples were analyzed using
1H-NMR Spectros-
copy. As a ﬁrst step PCA was applied to the resulting data.
However, PCA failed to reveal clustering based on disease
status. Further analysis of the loadings of ﬁrst two principal
components revealed that majority of the variation came
from differences in glucose concentration.
PLS discriminant analysis (PLS-DA) was then applied
to the data. The analysis of the ﬁrst three components
revealed clear separation between CLL and healthy sam-
ples. The loadings were studied and it was found that
increased levels of pyruvate, glutamate, proline, pyridoxine
and decreased concentration of isoleucine in CLL patients
were mainly responsible.
The possibility of using metabolomics analysis as a
predictor of IGHV status was then analyzed. Again PCA
was initially applied to the 19 CLL samples and mild
clustering was observed. Further analysis with PLS-DA
showed clear separation between the two groups. The
PLS-DA loadings showed that the unmutated IGHV sam-
ples had higher levels of cholesterol, lactate, uridine and
lower levels of pyridoxine and glycerol, among others.
Further NMR quantiﬁcation revealed statistically signiﬁ-
cant differences in concentrations of cholesterol, lactate,
methionine and pyridoxine between mutated and unmu-
tated IGHV patients.
4.2.4 Clustering
Cluster analysis, or clustering, refers to a whole host of
different algorithms that aims at dividing observations into
classes, or clusters based on a distance function. The goal
of a clustering algorithm is to partition the data into groups
so that the distances between the samples within each
group are small when compared to distances between
samples from different clusters.
The distance function is thought of as a measure of
dissimilarity. Different distance functions may be used;
the Euclidean distance is most often used in practice;
Manhattan distance is sometimes used as well.
Clustering algorithms can be divided into two types:
hierarchical and non-hierarchical. A non-hierarchical
clustering algorithm simply divides the data into clusters.
An example of this is K-means Clustering. We think of the
mean of samples in a cluster as the center of this cluster.
The K-means clustering algorithm divides the data into a
prescribed number of clusters (K) so that for each sample
the closest cluster center is the center of the cluster that it
belongs to. The number of clusters K comes from the data,
for example, if we want to divide into disease and healthy
groups, we would use two clusters, but if we have different
species or phenotypes then we can use a higher K.
In hierarchical clustering we start by thinking of each
sample as its own cluster. Then two closest clusters are
merged together and the process is repeated until all sam-
ples are in the same cluster. The way of deciding which
two clusters are closest depends on the hierarchical clus-
tering method used. For example, in Single Linkage hier-
archical clustering the distance between cluster A and
cluster B is the shortest distance between any sample in
cluster A and any sample in cluster B. Many other mea-
sures are possible, some of which involve distance between
centers of clusters as well distances between individual
samples.
A hierarchical clustering method outputs a dendrogram,
which records which clusters were joined together and at
what distance. This provides a visual description of the
evolution of the clusters.
Clustering methods are typically unsupervised. The
samples are divided into groups based on the distance
between them, without taking into account class labels. If
the data divides into groups along the lines of class labels
then this is a strong indication that the class division is
reﬂected in the data.
Clustering has been extensively used in genomics
studies and, therefore, can be readily adopted to study
metabolomics data.
Advantages of using clustering: Clustering is a well
established method and its various incarnations are avail-
able in a great variety of packages.
Downside of using clustering: Metabolomics data typi-
cally has variables of very different values. If the variables
are not rescaled then the various clusters will be deter-
mined by variables with large variance. The problem will
be similar to the one we encountered with using PCA: by
its nature metabolomics data have many extraneous vari-
ables, many of which will possess large variance. These
variables will strongly inﬂuence the performance of the
clustering algorithms.
Genomics data is typically log-transformed, thereby
greatly reducing the difference in values and variance
between the variables. However, log-transformation is
usually not performed with metabolomics data. A rescal-
ing, such as Pareto scaling we have seen in the PCA
application example, often needs to be performed to at least
partially eliminate the difference in variance between the
variables.
4.2.4.1 Example of using clustering: recognizing different
cancer cell lines from metabolomics data In Cuperlovic-
Culf et al. (2009) fuzzy K-means clustering was applied to
metabolomics data from breast cancer cell lines gathered
with
1H NMR spectroscopy. ‘‘Fuzzy’’ refers to the fact that
samples are not simply partitioned into K clusters, but
instead each sample is assigned a vector of K numbers,
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belongs to the corresponding cluster. We can also think of
these numbers as denoting the membership value between
the sample and each of the K clusters; the higher the
membership value the more likely the sample is to belong
to that cluster.
Five cell lines were used for the experiment, two cell
lines were grown from normal cells and three from cancer
cells; two of the cancer cell lines were from invasive
metastatic cancer and one from non-invasive cancer. Five
replicates were gathered for each cell line and the samples
were analyzed using
1H NMR spectroscopy. The spectrum
for each sample was separated into major peaks and the
peaks were matched with compounds using existing liter-
ature. Each peak was then integrated to calculate the total
presence for each compound.
When PCA was applied to these data and the two ﬁrst
principal components were plotted against each other it
was observed that there was clear separation between the
two normal cell lines and the three cancer cell lines. The
two normal cell lines were also separated from each other.
However the three cancer cell lines were mixed. Similar
results were observed when applying hierarchical cluster-
ing: the two normal cell lines formed crisp separated
clusters but the three cancer cell lines formed mixed
clusters. When regular K-means clustering (here with
K = 5 for the ﬁve cell lines) was applied the results were
inconclusive with different cell lines mixing between
clusters.
However, when the fuzzy K-means clustering was used
the two normal cell lines as well as the non-invasive cancer
cell line formed separate clusters based on the top mem-
bership value. The two invasive cell lines were mixed
based on the top membership value. However, the invasive
cell lines were clearly separated into two clusters based on
the second highest membership value. This shows the
potential of fuzzy clustering to not only divide the data into
a ﬁxed number of clusters but further subdivide it based on
phenotypes or other relevant characteristics.
4.2.5 Self organized maps
Self-Organized Map is a method of two-dimensional
visualization of the data. It is based on a speciﬁc kind of
neural network, where the neurons are arranged in a planar
or toroidal grid. We have already seen two methods of
two dimensional visualization: plotting two Principal
Components of PCA or PLS against each other. Both of
these methods are simply linear projections of the data.
Self-Organizing Map also generates a two dimensional
representation of the data, but it is capable of more com-
plex pattern recognition. The goal of SOM is to ﬁnd a good
two-dimensional representation of the data that is capable
of exploiting non-linear phenomena in the data. Since we
want not to just build a classiﬁcation ‘‘black box’’, but to
also understand the underlying biology of the problem, a
visualization of the data can provide very valuable insights.
SOM is an unsupervised method since it does not use
class labels in the construction of the map. A rectangular or
hexagonal grid of appropriate size needs to be chosen. A
typical SOM procedure consists of learning, where the
network is fed data from representative samples and visu-
alization where the network arranges new data based on
learned patterns.
An output of SOM is a 2-dimensional ‘‘map’’ where
samples that are similar to each other according to the data
analysis are placed in a similar region.
Advantages of using SOM: Self-Organizing Map pro-
vides a good visualization tool for the data. Unlike plots of
Principal components of PCA and PLS it can be used to
detect non-linear relationships in the data. It also does not
suffer from the tendency to select variables based on high
variance.
SOM is a very well established method with applica-
tions in many ﬁelds. The original application of SOM was
to voice recognition, but it has been extensively applied in
bioinformatics and medicine. There are a variety of soft-
ware packages that will build SOM from data.
Downside of using SOM: While SOM is capable of
exploiting non-linear relationships in the data, the indi-
vidual variables (metabolites) that are most responsible for
the classiﬁcation are not always easily read off. While GA
methods are speciﬁcally geared toward producing small
classiﬁcation models and it is possible to study the loadings
in PCA or PLS, the most important metabolites for SOM
are more hidden.
4.2.5.1 Example of SOM: examination of metabolic
changes in breast cancer tissue In study by Beckonert
and co-authors (Beckonert et al. 2003) metabolic changes
in human breast cancer tissue were examined. A total of 88
samples were collected consisting of 49 cancer tissue of
varying grade and 39 healthy samples. The samples were
analyzed using
1H NMR Spectroscopy. The resulting NMR
data for each sample was a vector of 1,057 components,
with 655 components corresponding to water-soluble
metabolites and 402 components corresponding to lipids.
Subsequently, feature selection was performed using
3-Nearest Neighbor Clustering to identify 62 metabolites
(features) that were promising in separating different
grades of cancer and healthy tissue. Three Nearest
Neighbor Clustering was used instead of PCA in hopes that
some low variance metabolites would be selected and
prove successful in differentiating different grades of
breast cancer and healthy tissue.
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with the 62 selected parameters. The map provided distinct
separation between the various grades of cancer. The upper
part of the map was taken up by the control samples, with
intermediate malignancy samples (grade 2) on the lower left
and high malignancy samples (grade 3) on the lower right.
Furthermore, the 62 underlying metabolites were ana-
lyzed to see whether each individually provides a picture
similar to the map built using the combination of all 62. For
each metabolite a different ‘‘concentration map’’ was built.
The concentration of a compound in a sample was shown
on the map as shade of gray, with white corresponding to
low concentration and black corresponding to high con-
centration. The compounds whose ‘‘concentration map’’
provided a picture similar to the SOM were judged to most
responsible for the classiﬁcation.
In water soluble metabolites it was seen that glucose and
myo-inositol were among the best differentiators between
healthy and malignant tissues, which was consistent with
earlier ﬁndings. Other potentially interesting differentiating
metabolites such as UDP sugar derivatives were identiﬁed.
In lipids there was a general increase in fatty acid con-
centration with tumor grade. Concentration of cholesterol
and glycerol, for example, showed a strong propensity to
increaseingrade3tumors.Thegeneralpictureofincreasein
fatty acids from healthy to tumor cells was again consistent
with earlier ﬁndings and gives evidence to the hypothesis
that fatty acids are synthesized within the tumor cells.
4.2.6 Genetic algorithms based methods
Genetic Algorithms (GA) methods are used to ﬁnd small
subsets of metabolites that are promising for distinguishing
betweengroupsofsamples,suchasidentifyingcancerversus
healthy samples. Unlike the methods discussed previously,
wenotonlywanttobuildaclassiﬁcationmodel,butwewant
to require that the model only uses a few metabolites. The
goal of these methods is more toward ‘‘biomarker discov-
ery’’, rather than just a classiﬁcation system.
When using PCA and PLS even if the data analysis
method is effective in classifying samples into groups, it is
not easy to single out a small subset of metabolites that is
responsible for the separation. The Principal Components
of PCA and PLS are linear combinations of all the vari-
ables, while in fact we expect to measure many parameters
that are unrelated to our problem when looking at the
entirety of the metabolome.
To address this problem, we can try to pick small sub-
sets of variables, and build a classiﬁcation model using just
these variables. The method used for building the small
model is up to the modeler; in practice Discriminant
Function Analysis (DFA) has been popular. However,
regardless of the method used, it is not computationally
possible to exhaustively search even all four or ﬁve vari-
able subsets, since the total number of variables we have is
in hundreds or thousands. This is where Genetic Algo-
rithms come in.
We do not need to try all the possible subsets, we just
need to produce the subsets that perform best for classiﬁ-
cation purposes. Genetic Algorithms provide an optimiza-
tion heuristic when exact optimization or exhaustive search
are computationally impossible.
GA based methods start with a small population of
subsets. For each subset a classiﬁcation model is built,
using a method such as DFA, and the accuracy of the
model or some other related property is used as its score.
Then the population is changed according to Genetic
Algorithm methods to try to optimize the choice of subsets
to provide the best classifying models. The algorithms
typically run for a ﬁxed number of steps after which the top
scoring subset is produced.
Genetic algorithms consist of three major steps: selec-
tion, crossover and mutation. During selection a subset of
the existing population is selected for reproduction. The
selection is based on a ﬁtness function, so in our case, the
best performing classifying small subsets are selected.
Typically, there is some randomness built in the selection
process to keep the algorithm from settling on a globally
poor local optimum.
In crossover a pair of ‘‘parent’’ subsets produces a new
‘‘child’’ subset. Then the subsets undergo mutation, where
a random change is made to the subset with a very small
probability. Once crossover and mutation are done, the
algorithm is repeated, until a ﬁxed number of iterations
(generations) is reached.
Due to the stochastic nature of Genetic Algorithms we
are unlikely to produce the same small subset of variables
every time. Instead the algorithm is run many times and we
analyze what variables are repeatedly chosen for the small
classiﬁcation models. The subsets of variables that are
chosen together in a high percentage of models are deemed
important for classiﬁcation.
Advantages of using GA methods: The main advantage
of GA based methods is that they produce classifying
models that use a small number of distinguishing variables
(metabolites). GA methods also do not suffer from the
propensity toward selecting variables with high variance,
which affects PCA.
Genetic Algorithm methods have been applied in many
ﬁelds, including analysis of microarray data, sequence
alignment, food science and civil engineering.
These methods also offer a lot of ﬂexibility; the Genetic
Algorithms can be coupled to any other supervised data
analysis method to produce a classiﬁcation model based on
a small subset of variables. The scoring of the models can
also be customized to improve performance.
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ber of variables in metabolomics data it is typical that
many small subsets are well suited for classiﬁcation. Some
subsets are present due to sheer randomness and small
sample size, while some are biologically meaningful. This
presents an added challenge in metabolomics since the
majority of peaks are unidentiﬁed. Therefore, it is not
always possible to decide whether a small subset has bio-
logical meaning without a major effort in terms of com-
pound detection. However, this is still a much better
situation than having a linear combination of all the vari-
ables, in which case we cannot hope to identify all of the
metabolites.
The ﬂexibility of GA models also has a downside since
there is no standard protocol and particular choices in the
implementation of the Genetic Algorithm, the classiﬁcation
method to be used, or method used to score the models will
inﬂuence performance of the data analysis. There is
available software that can perform, for example, GA-
DFA, but to our knowledge there are no packages that
would allow users to actually changes some of the
parameters we listed above and to see what impact these
changes will have.
4.2.6.1 Example of using genetic algorithms combined
with clustering: diagnosing ovarian cancer from serum
In Petricoin et al. (2002) Genetic Algorithms were com-
bined with clustering techniques to produce a method for
detection of early stage ovarian cancer based on patients’
serum. The method was constructed based on a data set of
100 patients, with 50 having various stages of ovarian
cancer and 50 control patients. None of the control samples
came from patients with gynecological disease or non-
gynecological inﬂammatory disorders. The serum was
analyzed using a SELDI-TOF mass spectrometer and for
each of the 100 samples a range of 15,200 m/z ratios with
corresponding intensities was calculated.
A genetic algorithm was applied to ﬁnd a small subset of
m/z ratios that best separates the cancer samples from
controls. The algorithm started with hundreds of random
choices of discriminating subsets consisting of ﬁve to
twenty m/z ratios each. The discriminating power of each
subset was analyzed using a clustering ﬁtness function. The
best ﬁt subsets were selected and their m/z ratios were
reshufﬂed to form new subsets until a fully discriminating
subset emerged.
The validation was performed using a set of 116 masked
samples, with 50 coming from patients with ovarian cancer
and 66 controls. The clustering technique, using the dis-
criminating m/z ratios constructed from the initial set, was
applied to the classiﬁcation of the samples in the masked
set. The samples were classiﬁed as either healthy, cancer or
new cluster if they were outside the margin error of either
cancer or healthy clusters of the initial set. The above
method correctly identiﬁed all 50 patients with ovarian
cancer. Of the 66 control samples 9 out of 10 patients with
gynecological disease were put into a new cluster, while
the 10th was put into the healthy cluster. Seven out of
seven patients with non-gynecological inﬂammatory dis-
order were placed into a new cluster. For the patients with
benign ovarian cysts, 24 out of 25 were correctly classiﬁed
as healthy and one classiﬁed as cancer. In the remaining 24
control samples 22 were correctly identiﬁed as healthy and
two were identiﬁed as cancer. The method achieved 100%
sensitivity on both the initial set and the masked set and
95% speciﬁcity. This example shows the power of genetic
algorithm methods, combined with supervised data analy-
sis, to ﬁnd a small discriminating subset and build a pre-
dictive model based on this subset.
5 Data integration
The proper tools to integrate data from different ‘‘omics’’
platforms is important as ‘‘omics’’ research is more widely
used as part of a systems biology approach and high
throughput platforms generate data for mathematical
modeling biochemical networks (for a recent review see
Mehrotra and Mendes 2006). The ability to analyze data
obtained at different levels, including transcripts, proteins
or metabolites, can provide deeper mechanistic insight into
biological systems. Integrated analysis of metabolite and
transcript or metabolite and protein levels has been used in
many systems and already identiﬁed important features of
metabolic regulation on different levels. Currently, most
metabolomics studies use largely either one, or a combi-
nation of two approaches, while integrated studies using a
combination of all three approaches are just appearing.
This, in many ways, is limited by the lack of proper data
analysis tools for integrated analysis of data from multiple
levels.
6 Software for metabolomics
By its nature metabolomics requires automated data pro-
cessing solutions. Although a series of commercial and
public tools exist, none of them provides a comprehensive
solution to meet the challenges of metabolomics. Selected
commercial and freely available software for metabolomics
is listed in Tables 1 and 2. More detail on each software
package can be found in a recent review by (Katajamaa and
Ores ˇic ˇ 2007) and in the references listed in the tables.
Many commercial software packages provide tools for
basic raw data processing as well as some kind of statistical
data analysis. Some packages incorporate unique and
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commercial or public software. The major limitation of
most commercial software supplied by equipment manu-
facturers is that it only works with a speciﬁc data format.
LECO Corporation’s ChromaTOF software package, for
example, provides superior deconvolution algorithms, but
it only works with the proprietary ﬁle format generated by
the LECO GC-TOF and LC-TOF instruments. This is a
major limitation for many metabolomics laboratories that
often utilize multiple analytical platforms and employ
instrumentation from different vendors. The other limita-
tion of the commercial software is that often the description
of a particular data processing algorithm is not available.
Recent development of publically available software
packages, including MZmine (Katajamaa et al. 2006),
XCMS (Smith et al. 2006), XCMS
2 (Benton et al.
2008), MathDAMP (Baran et al. 2006), and Met-IDEA
(Broeckling et al. 2006), expands vendor independent
bioinformatics solution for metabolomics data analysis.
MZmine software (Katajamaa et al. 2006) employs a
modular infrastructure with the ability to integrate new
algorithms and applications. Another publically available
package, XCMS (Smith et al. 2006), is implemented in R
language and is also available for download under GNU
General Public License. It provides noise ﬁltering, peak
detection, and non-linear spectral alignment algorithms as
well as statistical analysis of the data. The software can
process both GC–MS and LC–MS data. Recent extension
of the XCMS package called XCMS
2 added the capability
of automated searching of high quality MS–MS data
against METLIN database (Benton et al. 2008). In addition
to specialized software packages that were designed for
metabolomics application, several mass spectrometry data
processing software packages that were developed for
proteomics can also be used to process metabolomics data.
These include, among others, SpecArray (Li et al. 2005,
Table 1 Selected commercial software for metabolomics
Software Vendor Vendor web site
ACD MS Manager with IntelliXtract ACD/Labs http://www.acdlabs.com
ChromaTOF LECO www.leco.com
Genespring-MS Agilent http://www.opengenomics.com/
Ion Signature Quantitative Deconvolution
Software for Mass Spectrometry
Ion Signature Technology, Inc. http://ionsigtech.com/index.php
Ingenuity Pathways Analysis
(IPA)-IPA-Metabolomics
TM Analysis
Ingenuity Systems http://www.ingenuity.com/products/
ipa-metabolomics.html
MarkerLynx Waters http://www.waters.com/
MarkerView AB Sciex http://www3.appliedbiosystems.com/i
Mass Frontier ThermoFisher http://www.thermo.com/
Metabolomics Edition Bio-Rad http://www.bio-rad.com
SIEVE ThermoFisher http://www.thermo.com/
Table 2 Selected open access tools for complex LC/MS data analysis
Software name Reference Web address
BL-SOM (Kanaya et al. 2001) http://prime.psc.riken.jp/?action=blsom_index
Chrompare (Frenzel et al. 2003) http://www.chrompare.com/chrompare/
COMSPARI (Katz et al. 2004) http://www.biomechanic.org/comspari/
MathDAMP (Baran et al. 2006)
MeMo (Spasic et al. 2006) http://dbkgroup.org/memo/
MET-IDEA (Broeckling et al. 2006) http://noble.org/
MSFACTs (Duran et al. 2003) http://noble.org/
MZmine (Katajamaa and Ores ˇic ˇ 2005) http://mzmine.sourceforge.net/
TagFinder (Luedemann et al. 2008) http://www-en.mpimp-golm.mpg.de/
03-research/researchGroups/01-dept1/
Root_Metabolism/smp/TagFinder/index.html
XCMS (Smith et al. 2006) http://metlin.scripps.edu/download/
XCMS2 (Benton et al. 2008) http://mathdamp.iab.keio.ac.jp/
Bioinformatics tools for cancer metabolomics 339
123http://tools.proteomecenter.org/wiki/index.php?title=Soft
ware:SpecArray), MSight (Palagi et al. 2005, http://
www.expasy.org/MSight/), and MapQuant (Leptos et al.
2006, http://genepath.med.harvard.edu/mw/MapQuant).
7 Summary
Metabolomics, being a relatively new area of genomics
research, is rapidly gaining acceptance in many areas of
biomedical research, including cancer research. Recent
studies on metabolome changes during cancer develop-
ment and progression have already shown the feasibility
of using metabolomics for cancer diagnostics and prog-
nosis and identifying new targets for anticancer therapy
(Bathe et al. 2010; Borgan et al. 2010; Cascante et al.
2010; Catchpole et al. 2009; Howell, 2010; Madhok et al.
2010; Mamas et al. 2010; Slupsky et al. 2010; Sreekumar
et al. 2009; Wang et al. 2010; Zitvogel et al. 2010).
Despite the availability of many chemometric, statistical,
and machine learning tools for the analysis of metabolo-
mics data, many of them have important limitations, and,
therefore, there is an urgent need for better tools and
software. Further progress in cancer metabolomics greatly
depends on the improvement of analytical and bioinfor-
matics platform to improve sensitivity, speciﬁcity, me-
tabolome coverage and provide spatial and temporal
resolution for important metabolic changes in normal in
diseased state.
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